Angelini joins forces with JCR on brain-penetrant biologics for epilepsy

2023-05-11

并购引进/卖出

Angelini Pharma and JCR Pharmaceuticals on Thursday said they entered into an exclusive global agreement that applies the latter's blood-brain barrier penetrating technology J-Brain Cargo to develop novel biologic therapies for epilepsy. "Through this strategic collaboration…we will combine our respective strengths to explore the use of biologics in this area and accelerate critically needed treatment options," commented Angelini Pharma CEO Jacopo Andreose.

Under the agreed terms, JCR will be reimbursed for research expenses and receive an upfront payment. It is also eligible for additional payments of up to $505.5 million if certain development and commercial targets are achieved, as well as tiered royalties on post-approval net sales.

According to the companies, JCR's J-Brain Cargo technology allows the delivery of biotherapeutics into the central nervous system via receptor-mediated transcytosis. Following the preclinical development phase, Angelini Pharma will have an exclusive option to advance therapeutic candidates identified as part of the collaboration into clinical development and global commercialisation outside of Japan. JCR retains the right to commercialise in Japan.

In 2021, Angelini Pharma struck a deal to acquire Arvelle Therapeutics for up to $960 million, gaining rights to commercialise the epilepsy therapy cenobamate in Europe. The drug is used to treat drug-resistant focal-onset seizures in adults.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构